A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, SINGLE ASCENDING DOSE
STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY,
PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7812653
FOLLOWING INTRATHECAL ADMINISTRATION IN PARTICIPANTS
WITH EARLY SYMPTOMATIC ALZHEIMER’S DISEASE
- Registry ID
- BP45770
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- HOFFMANN-LA ROCHE LIMITED
- Start date
- 2026-06-08
- Last update
- 2025-08-22
Conditions
Related clinical trials
- A PHASE 1/2A PLACEBO-CONTROLLED DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ARO-MAPT-SC IN HEALTHY SUBJECTS AND SUBJECTS WITH EARLY ALZHEIMER’S DISEASE.
- PHASE 2/3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF EXV-802 AND EXV- 801 IN THE TREATMENT OF AGITATION IN PARTICIPANTS WITH ALZHEIMER’S DISEASE DEMENTIA
- A PHASE 1, RANDOMIZED, PLACEBO-CONTROLLED STUDY WITH A DOUBLE-BLIND PERIOD
WITH OPEN-LABEL EXTENSION PERIOD TO EVALUATE THE SAFETY, TOLERABILITY,
PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRATHECALLY ADMINISTERED ALN-
5288 IN ADULT PATIENTS WITH ALZHEIMER¿S DISEASE
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,
PARALLEL GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF
KARXT + KARX-EC FOR THE TREATMENT OF AGITATION ASSOCIATED
WITH ALZHEIMER’S DISEASE (ADAGIO-1)
- A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,
PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY
STUDY OF TRONTINEMAB IN PARTICIPANTS WITH EARLY
SYMPTOMATIC ALZHEIMER’S DISEASE (MCI TO MILD DEMENTIA DUE
TO AD)
- A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,
PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY
STUDY OF TRONTINEMAB IN PARTICIPANTS WITH EARLY
SYMPTOMATIC ALZHEIMER’S DISEASE (MCI TO MILD DEMENTIA DUE
TO AD)
View on source registry